Mylan Inc. has launched capecitabine tablets USP, 150 mg and 500 mg, the generic version of Genentech’s Xeloda. Mylan received final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers.

Capecitabine tablets USP, 150 mg and 500 mg, had U.S. sales of approximately $773.8 million for the 12 months ending June 30, 2014, according to IMS Health.

Source: Mylan